Repurposing & rare-disease

A working drug is a wasted drug, until it isn’t

The approved pharmacopeia contains roughly three thousand compounds with known pharmacology, regulatory clearance, manufacturing supply, and intact patent protection in selected indications. Most are sitting on incomplete value.

We screen catalogues against indications, not the other way around. Pick the hallmark — angiogenesis, telomere maintenance, immune evasion, fibrotic remodelling, dysregulated metabolism — and the body model returns the candidates whose pharmacology hits that hallmark with the dose envelope to do so safely.

Indications we have worked

• Cancer hallmarks: all fourteen Hanahan–Weinberg targets explicitly modelled and queryable
• Rare neurology: vascular dementia, glymphatic dysfunction, multiple-sclerosis subtypes
• Orphan endocrine: thyroid-storm rescue, primary adrenal insufficiency variants
• Geriatric polypharmacy: candidate withdrawals from drug regimens that are quietly cancelling each other

What this is not

A connectivity-map gene-expression screen. Those produce long candidate lists that mostly fail because expression matching is not pharmacology. We screen the pharmacology directly.